volume 6, issue S1, PS163-S167 2017
DOI: 10.21037/tcr.2017.01.35
View full text
|
|
Share

Abstract: PANCREOX trial and second-line treatment after gemcitabine-based first-linePancreatic cancer is an extremely aggressive disease, projected to become the second leading cause of cancerrelated death (1). While the attempt of using a personalized approach in first line setting failed, the intensification of the treatment, by the use of the combination of gemcitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and the triplet regimen FOLFIRINOX (a combination of 5-fluorouracil (5-FU), leucovorin, i…

expand abstract